Figure 4 | Scientific Reports

Figure 4

From: Extracellular vesicles produced in B cells deliver tumor suppressor miR-335 to breast cancer cells disrupting oncogenic programming in vitro and in vivo

Figure 4

(A) Expression of miR-335 and SOX4 in LM2 cells treated with iEVs-335, scramble iEVs or sham EVs for 2 days (D2 on) and subsequently on day 4 and 8 following removal of iEVs (D4 off and D8 off). (B) Whole transcriptome analysis of iEVs-335 treatment of LM2 cells. A heatmap showing relative expression of SOX4 and target genes in LM2 cells 4 days post-treatment (D4 off) with iEVs-335, iEVs-scrambled, sham EVs and untreated. Log2 gene expression values were converted to z-scores. Color in the heatmap indicates the mean z-score across replicates from the same condition. Genes that are significantly differentially expressed in iEV-335 treated LM2 cells relative to the pooled control conditions are indicated with*. (C) Relative quantification (RQ) of MMP1, FSCN1 and TGFβ in LM2 cells treated with iEVs-335 4 days after removal of treatment. (D) TGFβ signaling via SMAD genes colored according to log 2 fold change in gene expression between miR-335 treated and control conditions. Significantly up- or down-regulated genes in iEVs-335 treated LM2 cells relative to control conditions are indicated by red text.

Back to article page